Theranostics Market

The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing establishment of hospitals, rising focus on targeted therapies, and introduction of novel theranostic approaches are expected to drive the market during the forecast period. Introduction of artificial intelligence (AI) helps to improve the diagnostic accuracy. Recent FDA approvals increases the awareness and supports rising adoption of theranostics.

Global Theranostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

e- Estimated; p- Projected

Theranostics Market: Market Dynamics

Driver: Rising focus on precision medicine to propel the market

Precision medicine or personalized medicine involves the targeted approach for a patient by considering the difference in the genes and other factors such as lifestyles and environments. Specific characteristics of a patient are analyzed tailored for innovative approach to medical treatment. The treatment or therapy designed for the patient by considering the molecular and cellular profile results in effective prevention, diagnosis, improved outcomes, and reduced side effects.

Theranostics, a combination of diagnostics and therapy, emphasizes individualized and targeted therapies. Theranostics and precision medicine proves to be helpful with the better management of patients suffering through cancer. Specific biomarkers are identified to know the patient’s response to the treatment. This helps healthcare professionals with decisions such as drug selection that leads to higher treatment success rates. Identification of molecular basis of the disease in precision medicine is supported by theranostics. Theranostics provides diagnostic tools that helps with identifying the patients that are best suited for the treatment. Hence, rising incidents of cancer and increasing focus on presonlized treatment is anticipated to propel the market in future.

Restraint: Short half-life of radiopharmaceuticals

The expiry of a radiopharmaceutical primarily depends on the half-life of the radioisotope and the content of the radionuclide. For example, the radioactivity of F-18 decreases if not used within 110 minutes, while the radioactivity of C-11 decreases within 20 minutes. Whereas the radioactivity of Tc-99m is reduced after six hours, while I-123 and In-111 isotopes should be utilized within 13 and 67 hours, respectively. The non-utilization of radioisotopes within the prescribed shelf life causes radiation and chemical decomposition. This leads to reduction in the radiochemical purity to an unacceptable form, which may prove fatal during diagnosis and therapy. As a result, the geographic locations of the production site and usage site of radioisotopes have to be proximate. This increases the investment required for the establishment of production facilities. Additionally, the shorter half-life of radiopharmaceuticals creates a need for in-house radiopharmaceutical production in cyclotrons/generators within hospital premises, further increasing the capital expenditure for hospitals.

Opportunity: Growth opportunities in emerging countries

Developing economies such as offer growth opportunities for the major players in the market. Although the cost factor is a concern in these developing countries, their huge population base—especially in India and China—offers a sustainable market for theranostics.

The high incidence of chronic diseases such as cancer, strokes, and neurological and cardiovascular diseases, as well as the high death rates in these countries, have increased the need for early detection. According to a GLOBOCAN 2020 report, the number of new cancer cases diagnosed in 2020 was 19.3 million, and almost 10.0 million died due to cancer.

Key market players are adopting various growth strategies to strengthen their foothold in this region. For instance, in August 2019, Eckert & Ziegler (Germany) initiated a joint venture with Chengdu New Radiomedicine Technology Co., Ltd. (China) to set up a new production facility for radiopharmaceuticals used in the treatment of hepatocellular carcinomas in China. According to an article published in the European Journal of Nuclear Medicine and Molecular Imaging 2022, by 2025, about 50 new centralized radiopharmacies will be built across China, and the availability and accessibility of radiopharmaceuticals will be significantly improved by then.

All these factors are expected to offer growth opportunities for players operating in the market.

Challenge: Shortage of trained professionals

The rising cost of prescription drugs and a sharp decline in the proposed budget allocations for Health and Human Services in the US have significantly reduced hospital budgets. A study by the American Hospital Association estimates that federal payment cuts to hospitals would amount to USD 218 billion by 2028, forcing hospitals to allocate smaller budgets annually.

Healthcare facilities that purchase expensive equipment such as cyclotron or nuclear reactors and radiotracers often depend on third-party payers (such as Medicare, Medicaid, or private health insurance plans) to avail reimbursements for costs incurred in diagnostic, screening, and therapeutic procedures performed with these devices. However, continuous cuts in the reimbursement and the increasing cost of radiotracers due to their limited availability prevent imaging centers from investing in these modalities.

Moreover, owing to the high cost of the equipment, most hospitals in developing countries are unable to afford this highly sophisticated technology. Due to the high cost of these systems and financial limitations, healthcare facilities such as small hospitals and cancer care centers are reluctant to invest in this equipment. This will force them to focus on lower-priced alternatives, such as refurbished devices or upgrades of existing devices.

Market Ecosystem

By product, the diagnostic imaging segment of theranostics industry accounted for the largest share in 2022.

Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. In 2022, the diagnostic imaging segment accounted for the largest market share. The rising use of advanced instruments supporting accurate diagnosis and availability of systems with better sensitivity is driving the segment growth.

By application, the prostate cancer segment of theranostics industry to register significant growth in the near future.

Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. Prostate cancer segment to register the highest growth rate during the forecast period. The major factors responsible for the highest growth rate of this segment are the rising incidence of prostate cancer and increasing investments and funds related to cancer.

By end user, the hospitals segment of theranostics industry accounted for the largest share in 2022.

Based on end user, the global theranostics market is segmented into hospitals and cancer care centers, theranostics centers, and research and academic centers. In 2022, hospitals and cancer care segment accounted for the largest market share. The highest share of this segment is attributed to the rising aoption of theranostic treatment at the hospitals for and increasing awareness regarding benefits of the treamtment. This is primarily attributed to the recent approvals and the rising adoption advanced diagnostic imaging systems with improved features in hospitals supporting patient care.

Theranostics Industry By region, North America is expected to be the largest market during the forecast period.

North America accounted for the largest share of the Theranostics Market in 2022. Factors such as rising cancer incidence and rising number of investments supporting increasing adoption of theranostics is driving the market growth. Rapid growth in the old age population in the region and establishment of the theransotics centers are supporting the growth of the market.

To know about the assumptions considered for the study, download the pdf brochure

As of 2022, prominent players in the market are Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).

Scope of the Theranostics Industry:

This report has segmented the global theranostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Diagnostic Imaging
• Radiopharmaceuticals
• IVD/Biomarker Screening
• Software and Services

By Application

• Prostate Cancer
• Bone Metastasis
• Other Cancers
• Other Applications

By End User

• Hospitals and Cancer Care Centers
• Theranostics Centers
• Research and Academic Centers

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Rest of Europe
    • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments of Theranostics Industry:

• Advanced Accelerator Applications (France) received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan). Pluvicto is a targeted radioligand therapy for patients with prostate cancer with a therapeutic radioisotope.
• Bayer AG (Germany) and the Broad Institute of MIT and Harvard (US) extended their long term collaboration for the advancement of new therapeutic approaches in cancer.
• GE Healthcare collaborated with the Mayo Clinic (US) for innovation in research and product development. The collaboration aims to have the technology for clinicians for the precise diagnosis and approaches to theranostics and medical imaging.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst